CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

GlobeNewswire Clinical Studies
Original article

Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer

FDA Decision
Related Companies

Read the original article

Published by GlobeNewswire Clinical Studies on July 14, 2026 8:53 PM

Read Original